NoPeanutsPlease is an independent blog.

All views, opinions and conclusions are solely those of the author and do not imply endorsement or recommendation by any other party.

Saturday, February 24, 2007


I posted in January about current peanut allergy research. I noted that Xolair, an asthma treatment that nets Genentech over $400M per year in revenue, could possibly be used in the treatment of anaphylactic food allergies. However, I did note that the cost of the annual treatment could be as high as $10k.

This week the FDA required a warning label for Xolair due to the drug apparently causing anaphylaxis in some patients (specifically it occurred in approximately 'one in a thousand cases').

I suspect that a drug that causes anaphylaxis in some patients, however remote the risk is, might not be useful in the treatment of anaphylaxis. Perhaps Genetech will now revisit research into TNX-901?


Len said...

This will be a interesting topic. Please keep us posted.

Lisa said...

It is definitely interesting that Genentech has now acquired Tanax. I am hoping since the Xolair trials have been unsuccessful at treating peanut allergy Genentech realizes we are dying to buy TNX-901.